SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $1,095,100,823 |
| Positions | 47 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| Trevi Therapeutics Inc | TRVI | Common | $95,015,558 | 5,094,668 |
| Praxis Precision Medicines | PRAX | Common | $90,766,926 | 271,116 |
| Erasca Inc | ERAS | Common | $75,614,188 | 4,127,412 |
| Arrivent BioPharma Inc | AVBP | Common | $58,436,050 | 1,682,097 |
| Abivax SA - ADR | ABVX | SPONSORED ADS | $55,289,441 | 414,899 |
| Tango Therapeutics Inc | TNGX | Common | $43,131,579 | 1,379,769 |
| Corvus Pharmaceuticals Inc | CRVS | Common | $41,918,891 | 2,805,816 |
| Bright Minds Biosciences Inc | DRUG | Common | $39,113,474 | 557,172 |
| Sinovac Biotech Ltd. | Unresolved | SHS | $38,192,410 | 5,903,000 |
| Tenax Therapeutics Inc | TENX | Common | $36,375,000 | 2,500,000 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.